RJA
IGMS

Raymond James & Associates’s IGM Biosciences IGMS Stock Holding History

Raymond James & Associates’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-41,348
Closed -$568K – 3898
2023
Q1 		$568K Sell
41,348
-1,168
-3% -$24.2K ﹤0.01% 2842
2022
Q4 		$723K Buy
42,516
+1,883
+5% +$37.7K ﹤0.01% 2631
2022
Q3 		$924K Buy
40,633
+1,900
+5% +$38.4K ﹤0.01% 2451
2022
Q2 		$698K Sell
38,733
-1,334
-3% -$23.8K ﹤0.01% 2695
2022
Q1 		$1.07M Buy
40,067
+19,067
+91% +$355K ﹤0.01% 2545
2021
Q4 		$616K Buy
21,000
+533
+3% +$26.5K ﹤0.01% 2937
2021
Q3 		$1.35M Buy
20,467
+39
+0.2% +$2.98K ﹤0.01% 2383
2021
Q2 		$1.7M Buy
20,428
+50
+0.2% +$3.7K ﹤0.01% 2214
2021
Q1 		$1.56M Sell
20,378
-335
-2% -$30.5K ﹤0.01% 2184
2020
Q4 		$1.83M Sell
20,713
-10,339
-33% -$727K ﹤0.01% 1936
2020
Q3 		$2.29M Sell
31,052
-250
-0.8% -$14.8K ﹤0.01% 1665
2020
Q2 		$2.29M Hold
31,302
– – ﹤0.01% 1659
2020
Q1 		$1.76M Sell
31,302
-1,304
-4% -$57.2K ﹤0.01% 1646
2019
Q4 		$1.24M Buy
+32,606
New +$819K ﹤0.01% 2142

Other funds holding IGMS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James & Associates's IGMS Position: Q2 2023 in Review

Raymond James & Associates sold out of IGM Biosciences (IGMS) in Q2 2023, closing a stake of 41,348 shares — an estimated $568K sold.

Raymond James & Associates first reported a position in IGMS in Q4 2019 and held it in 14 quarters. The position peaked at $2.29M in Q3 2020. 79 funds tracked by Wall St. Rank hold IGMS as of Q2 2023.

  • Raymond James & Associates reported no remaining IGM Biosciences position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 41,348 IGM Biosciences shares in Q2 2023, an estimated $568K.
  • Raymond James & Associates first reported a position in IGM Biosciences in Q4 2019 and held it in 14 quarters.
  • Raymond James & Associates's IGM Biosciences position peaked at $2.29M in Q3 2020.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.